Sleep Disorders

The associate chief of the MS division and professor of neurology at the University of Pennsylvania described the relationship between artificial intelligence and medicine, and how he sees it evolving in the future.

Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.

With its FDA approval, the selective histamine 3 receptor antagonist/inverse agonist, branded Wakix, is the first and only therapy for narcolepsy which is not scheduled as a controlled substance by the DEA. It is expected to enter the market by Q4 2019.

New study findings confirm that idiopathic rapid‐eye‐movements sleep behavior disorder and RBD secondary to narcolepsy type 1 can be identified via video‐polysomnography and skin biopsy for phosphorylated α‐synuclein deposits.

Mind Moments® a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.

On our anniversary, take a look back at some of our most popular articles and interviews across a range of neurology topics.

The Drowzle algorithm was tested against polysomnography results and provided a sensitivity of 93.7% to detect moderate and severe obstructive sleep apnea.

People who did not use trazodone had up to a 2-fold faster decline in MMSE score than those who used the drug.

The International Congress on the Future of Neurology will take place this Fall in New York City, converging experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.

As home-monitoring devices become more available, accessible, and useful, they are increasing becoming helpful in neurological decision-making. More in this video.

The head of neurology at the Sunnybrook Health Sciences Centre of the University of Toronto spoke about the limited available normative sleep data, and shared insight into the findings of the meta-analysis he and colleagues conducted of more than 150 studies.

The mean decrease from baseline in latency to persistent sleep was 15 minutes for placebo, 30 minutes for seltorexant 5 mg, 50 minutes for 10 mg, and 48 minutes for 20 mg.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about one of the major symptoms of narcolepsy and how to identify it during diagnosis.

Sleep apnea and other sleep disorders are increasingly being recognized as major factors in the etiology and treatment of a host of neurological diseases, but awareness in the neurology community still has room to grow.

Several poster presentations at IEC 2019 suggest that the incidence of comorbid sleep disorders in people with epilepsy is higher than estimated and have a detrimental impact on quality of life and social adjustment.

Neurology News Network for the week ending June 22, 2019.

Four of the 7 patients exhibited significant improvement in all assessed study parameters, which included reduction in the Apnea-Hypopnea Index scale and an improvement in oxygen desaturation index, with 1 patient demonstrating mild improvement; overall THX-110 was generally well tolerated.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.

The director of the center for circadian and sleep medicine at Northwestern University spoke about the importance of recognizing insomnia as a clinical diagnosis since it affects patients 24-hours a day, not just during sleep.

Solriamfetol (Sunosi, Jazz Pharmaceuticals) is expected to be available in July 2019 in the United States.

Neurology News Network for the week ending June 15, 2019.

All told, every patient with RLS in the study had SIBO present, in comparison to general population rates which range from roughly 6% to greater than 15%.

Use of prescription antidepressants and hypnotics was significantly reduced in patients who underwent digital cognitive behavioral therapy for insomnia.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center spoke about the challenges in diagnosing narcolepsy, which often adds to the delay of diagnosis.

Investigators noted that, when considered with efficacy findings in narcolepsy, pitolisant has a favorable risk-benefit profile representative of advancement in the treatment of excessive daytime sleepiness and cataplexy in adult patients.

The autonomic disorders and sleep medicine specialist at Stanford University spoke about the overlap of autonomic disorders in sleep medicine, an often underrepresented portion of the sleep medicine field.

The findings suggest that the benefits of CPAP adherence may translate beyond improving obstructive sleep apnea in older adults with mild cognitive impairment.

The investigational dual-orexin antagonist from Eisai was significantly better at reducing Insomnia Severity Index-measured symptom severity in more than 1000 adults with insomnia in 2 phase 3 studies.

The efficacy of CBT using the American Academy of Sleep Medicine (AASM) SleepTM platform has been shown to be similarly efficacious to face-to-face physician encounters in 30 adults with chronic insomnia.